Notch Inhibitors Market: Competitive Landscape, Pipeline, and Market Analysis 2024

The Notch signaling pathway is a highly conserved cell signaling system present in most animals. Mammals possess four different notch receptors, referred to as NOTCH1, NOTCH2, NOTCH3, and NOTCH4. The notch receptor is a single-pass transmembrane receptor protein. Notch signaling promotes proliferative signaling during neurogenesis, and its activity is inhibited by numbing to promote neural differentiation. It plays a major role in the regulation of embryonic development. The Notch pathway plays a critical role in various cellular processes, including cell proliferation, differentiation, and apoptosis. Dysregulation of this pathway has been associated with several diseases, including cancer, cardiovascular disorders, and neurodegenerative conditions. The mechanism of action of Notch inhibitors involves blocking or interfering with the activity of Notch receptors or downstream signaling components.

Notch Inhibitors are used in the treatment of acute myelogenous leukemia, lymphoma, sarcoma, chronic myeloid leukemia, acute lymphocytic leukemia, adrenal diseases, blood coagulation disorders, breast diseases, and CNS neoplasms to name a few. Moreover, the increasing prevalence of leukemia and lymphoma, and increasing R&D investments are the key drivers for the Notch Inhibitors market. For instance, according to the World Cancer Research Fund 2020, There were an estimated 18.1 million cancer cases around the world and 4,74,519 new cases of leukemia in 2020. The global cancer burden is expected to be 28.4 million cases in 2040, a 47% rise from 2020. Moreover, the development of novel molecules by many market players is coming up to overcome challenges in therapy. For instance, Roche’s RG4733 for the treatment of lung cancers is in the various stages of clinical studies.

Key Market Developments:

• In May 2023, Hyundai Bioscience completed phase 2, clinical study of CP-COV03 (Niclosamide) for COVID-19.

Drugs under the Pipeline for Notch Inhibitors:

• RG4733
• Crenigacestat (LY3039478)
• AL101
• Niclosamide (DWRX2003)
• CB-103
• Brontictuzumab (OMP-52M51)
• Niclosamide Novel Solution
• AL102
• AUD1001
• MK-0752
• Niclonex (Niclosamide Suspension)
• SL-201
• Niclosamide Inhalation (UNI91104)

Clinical Activity and Developments of Notch Inhibitors:

Till July 2023, more than 15 companies have approximately 14 molecules targeting the many cancers. For these molecules, more than 19 clinical trials are being conducted and the majority are in phase-2, and phase-3 clinical trials by the players across the globe. For instance, In July 2018, Eli Lilly has completed a phase 1b/randomized phase 2 study to evaluate LY3039478 in combination with Dexamethasone in T-ALL/T-LBL patients.